Sandoz Submits Generic Tirzepatide Applications to FDA

Sandoz has submitted two abbreviated new drug applications to the FDA for generic versions of tirzepatide, the active ingredient in popular diabetes and weight-loss medications Mounjaro and Zepbound. This move could increase access to GLP-1 receptor agonists for type 2 diabetes and weight management. The acceptance of these applications marks a step towards potential generic availability.